- Artelo indicated it will defer the planned securities offering for the moment.
- The company confirmed no shares were sold and may consider fundraising later.
- On Thursday, Artelo said it plans to test ART27.13 for preserving muscle in GLP-1 patients.
Artelo Biosciences, Inc. (ARTL) has formally requested the withdrawal of its recently effective registration statement for a planned securities offering, signaling a pause in its capital-raising efforts.
On Friday, the company submitted a request under Rule 477 of the Securities Act of 1933 to withdraw its Form S-1, initially filed with the U.S. Securities and Exchange Commission on March 20 and declared effective on March 25.
Artelo Pauses Proposed Securities Offering
Artelo stated that it does not plan to move forward with the proposed securities offering at this time. The company emphasized that no shares were issued or sold under the registration statement, and it intends to revisit capital-raising options in the future when conditions are more favorable.
Following the update, Artelo Biosciences stock traded over 154% higher on Friday morning. On Stocktwits, retail sentiment around the stock changed to ‘extremely bullish’ from ‘bullish’ territory the previous day amid ‘extremely high’ message volume levels.
Strategic Expansion Initiative
On Thursday, Artelo announced plans to explore a new application for its ART27.13 compound. The therapy targets muscle preservation in patients undergoing glucagon-like peptide-1 (GLP-1) receptor agonist treatment to address lean body mass loss.
The initiative builds on multiple promising developments. ART27.13 demonstrated protective effects on muscle in the CAReS trial, showing increased lean body mass and enhanced physical activity in cancer anorexia and cachexia patients.
Artelo Biosciences is a clinical-stage pharmaceutical company focused on treatments for cancer, pain, dermatologic, and neurological conditions.
ARTL stock has gained over 170% year-to-date.
Also See: Entergy, Meta Ink Agreement To Fund New Gas Plants For Louisiana AI Data Center
For updates and corrections, email newsroom[at]stocktwits[dot]com.